134 related articles for article (PubMed ID: 10389653)
21. The hepatitis B virus-trimera mouse: a model for human HBV infection and evaluation of anti-HBV therapeutic agents.
Ilan E; Burakova T; Dagan S; Nussbaum O; Lubin I; Eren R; Ben-Moshe O; Arazi J; Berr S; Neville L; Yuen L; Mansour TS; Gillard J; Eid A; Jurim O; Shouval D; Reisner Y; Galun E
Hepatology; 1999 Feb; 29(2):553-62. PubMed ID: 9918935
[TBL] [Abstract][Full Text] [Related]
22. A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels.
Wiegand J; Wedemeyer H; Finger A; Heidrich B; Rosenau J; Michel G; Bock CT; Manns MP; Tillmann HL
Antivir Ther; 2008; 13(4):547-54. PubMed ID: 18672533
[TBL] [Abstract][Full Text] [Related]
23. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.
Benhamou Y; Katlama C; Lunel F; Coutellier A; Dohin E; Hamm N; Tubiana R; Herson S; Poynard T; Opolon P
Ann Intern Med; 1996 Nov; 125(9):705-12. PubMed ID: 8929003
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients.
Guptan RC; Thakur V; Kazim SN; Sarin SK
J Gastroenterol Hepatol; 2002 Jul; 17(7):765-71. PubMed ID: 12121506
[TBL] [Abstract][Full Text] [Related]
25. Anti-hepatitis B virus activity of wogonin in vitro and in vivo.
Guo Q; Zhao L; You Q; Yang Y; Gu H; Song G; Lu N; Xin J
Antiviral Res; 2007 Apr; 74(1):16-24. PubMed ID: 17280723
[TBL] [Abstract][Full Text] [Related]
26. [Effect of echinacoside on replication and antigen expression of hepatitis B virus].
Dai LH; Shen YM; Wu YH; Yu XP; Hu HJ; Mi YJ; Chen JJ
Zhongguo Zhong Yao Za Zhi; 2015 Aug; 40(15):3047-52. PubMed ID: 26677709
[TBL] [Abstract][Full Text] [Related]
27. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.
Lai CL; Ching CK; Tung AK; Li E; Young J; Hill A; Wong BC; Dent J; Wu PC
Hepatology; 1997 Jan; 25(1):241-4. PubMed ID: 8985298
[TBL] [Abstract][Full Text] [Related]
28. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.
Bowden S; Locarnini S; Chang TT; Chao YC; Han KH; Gish RG; de Man RA; Yu M; Llamoso C; Tang H
World J Gastroenterol; 2015 Apr; 21(15):4644-51. PubMed ID: 25914474
[TBL] [Abstract][Full Text] [Related]
29. [Effects of lamivudine and interferon-alpha combination therapy on chronic hepatitis B].
Tang Y; Chen G; Zheng R
Zhonghua Gan Zang Bing Za Zhi; 2002 Apr; 10(2):89. PubMed ID: 11983118
[No Abstract] [Full Text] [Related]
30. Hepatitis B virus transgenic mice for the model of anti-hepatitis B virus drug study.
Xiong Y; Jia Y; Wang H; Liu G; Ren H; Zhuo Z; Zhang D
Zhonghua Gan Zang Bing Za Zhi; 2001 Feb; 9(1):19-21. PubMed ID: 11242128
[TBL] [Abstract][Full Text] [Related]
31. Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy.
Ho EY; Yau T; Rousseau F; Heathcote EJ; Lau GK
Hepatol Int; 2015 Apr; 9(2):224-30. PubMed ID: 25788197
[TBL] [Abstract][Full Text] [Related]
32. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.
Chan HL; Wong VW; Tse AM; Tse CH; Chim AM; Chan HY; Wong GL; Sung JJ
Clin Gastroenterol Hepatol; 2007 Dec; 5(12):1462-8. PubMed ID: 18054753
[TBL] [Abstract][Full Text] [Related]
33. High persistence rate of hepatitis B virus in a hydrodynamic injection-based transfection model in C3H/HeN mice.
Peng XH; Ren XN; Chen LX; Shi BS; Xu CH; Fang Z; Liu X; Chen JL; Zhang XN; Hu YW; Zhou XH
World J Gastroenterol; 2015 Mar; 21(12):3527-36. PubMed ID: 25834317
[TBL] [Abstract][Full Text] [Related]
34. [Effects of antiviral agents on intrahepatic ccc DNA in HBeAg-positive chronic hepatitis B patients].
Lu HY; Zhuang LW; Yu YY; Si CW; Li J
Zhonghua Gan Zang Bing Za Zhi; 2008 Mar; 16(3):198-202. PubMed ID: 18364079
[TBL] [Abstract][Full Text] [Related]
35. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.
Buti M; Elefsiniotis I; Jardi R; Vargas V; Rodriguez-Frias F; Schapper M; Bonovas S; Esteban R
J Hepatol; 2007 Sep; 47(3):366-72. PubMed ID: 17561304
[TBL] [Abstract][Full Text] [Related]
36. Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.
Koffi J; Egounlety R; Pradat P; Lebosse F; Si-Ahmed SN; Lussier V; Chevallier P; Bailly F; Zoulim F
Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):146-54. PubMed ID: 24025974
[TBL] [Abstract][Full Text] [Related]
37. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients.
Lee WC; Wu MJ; Cheng CH; Chen CH; Shu KH; Lian JD
Am J Kidney Dis; 2001 Nov; 38(5):1074-81. PubMed ID: 11684562
[TBL] [Abstract][Full Text] [Related]
38. HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine resistance.
Shin JW; Jung SW; Park BR; Kim CJ; Eum JB; Kim BG; Du Jeong I; Bang SJ; Park NH
Antivir Ther; 2012; 17(2):387-94. PubMed ID: 22293395
[TBL] [Abstract][Full Text] [Related]
39. Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy.
Hacker HJ; Zhang W; Tokus M; Bock T; Schröder CH
Ann N Y Acad Sci; 2004 Jun; 1022():271-81. PubMed ID: 15251972
[TBL] [Abstract][Full Text] [Related]
40. Perspectives for the treatment of hepatitis B virus infections.
De Clercq E
Int J Antimicrob Agents; 1999 Jul; 12(2):81-95. PubMed ID: 10418752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
